Circulating Biomarker for Liquid Biopsy Market Report 2024 (Global Edition)

Global Circulating Biomarker for Liquid Biopsy Market Report 2024 Market Size Split by Diagnosis Method (Blood Tests, Saliva Tests, Exhaled Breath Tests, Urine Tests, Other Tests), by Application (Can...

Circulating Biomarker for Liquid Biopsy Market Report Description

We have various report editions of Circulating Biomarker for Liquid Biopsy Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Circulating Biomarker for Liquid Biopsy Market Insights Video

Competitive Landscape of the Circulating Biomarker for Liquid Biopsy Market

The liquid biopsy circulating biomarker market is characterized by a highly competitive landscape with multiple leading companies vying for market dominance and technical developments. Businesses prioritize innovation in the creation of assays, biomarker identification, and strategic alliances. Prominent companies such as Sysmex Corporation (Japan) , Menarini Silicon Biosystems (Italy) , Natera, Inc. (US) prioritize diversifying their product lines and improving the precision of diagnosis. Significant R&D expenditures are also being made in the market, which is creating a competitive climate with the goal of advancing personalized treatment and early cancer detection.

Top Companies Market Share in Circulating Biomarker for Liquid Biopsy Industry: (In no particular order of Rank)

• F. Hoffmann-La Roche Ltd (Switzerland)
• Thermo Fisher Scientific Inc. (US)
• QIAGEN N.V. (Netherlands)
• Illumina
• Inc. (US)
• Guardant Health
• Inc. (US)
• Biocept
• Inc. (US)
• Sysmex Corporation (Japan)
• Menarini Silicon Biosystems (Italy)
• Natera
• Inc. (US)
• GRAIL
• Inc. (US)
• Biocartis Group NV (Belgium)
• Personal Genome Diagnostics Inc. (US)
• Exosome Diagnostics
• Inc. (US)
• Bio-Rad Laboratories
• Inc. (US)
• Genomic Health
• Inc. (US)
• RainDance Technologies
• Inc. (US)
• OncoCyte Corporation (US)
• Adaptive Biotechnologies Corporation (US)
• Angle plc (United Kingdom)
• Epic Sciences
• Inc. (US)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Circulating Biomarker for Liquid Biopsy Market

Which Region Dominates the Circulating Biomarker for Liquid Biopsy Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. North America's circulating biomarker for liquid biopsy market is expanding unexpectedly because of advanced healthcare infrastructure, increased cancer incidence, and a growing emphasis on non-invasive diagnostics. The vicinity advantages from vast investments in research and development, alongside a strong call for early cancer detection and personalized remedy, riding the marketplace's increase and innovation.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Circulating Biomarker for Liquid Biopsy market. Asia Pacific s circulating biomarker for liquid biopsy market is growing because of improvements in biotechnology, supportive regulatory frameworks, and growing cancer incidence. Enhanced research efforts and accelerated cognizance of non-invasive diagnostic strategies are driving marketplace growth. The region's consciousness of personalized medicine and early detection is also contributing to the growth and innovation in this area.

The current report Scope analyzes Circulating Biomarker for Liquid Biopsy Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Circulating Biomarker for Liquid Biopsy Market

According to Cognitive Market Research, the global Circulating Biomarker for Liquid Biopsy market size was estimated at USD XX Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.8% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Circulating Biomarker for Liquid Biopsy market with a market size of USD XX million in 2024 and is projected to grow at a CAGR of 10.6% during the forecast period. The nation's early cancer detection.
• The Canada Circulating Biomarker for Liquid Biopsy market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 11.6% during the forecast period. Canada's non-invasive testing.
• The Mexico Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 11.3% during the forecast period, with a market size of USD XX million in 2024.

Europe Circulating Biomarker for Liquid Biopsy Market

According to Cognitive Market Research, the global Circulating Biomarker for Liquid Biopsy market size was estimated at USD XX Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.1% from 2024 to 2031.

• The United Kingdom Circulating Biomarker for Liquid Biopsy market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 11.9% during the forecast period. In the UK, Circulating Biomarker for Liquid Biopsy sales witness an upswing due to the technological advancements.
• The France Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD XX million in 2024.
• According to Cognitive Market Research, the German Circulating Biomarker for Liquid Biopsy market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 11.3% during the forecast period. In Germany, Circulating Biomarker for Liquid Biopsy surged due to the personalized medicine.
• The Italy Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 10.5% during the forecast period, with a market size of USD XX million in 2024.
• The Russia Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 10.1% during the forecast period, with a market size of USD XX million in 2024.
• The Spain Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 10.2% during the forecast period with a market size of USD XX million in 2024
• The Luxembourg Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 11.2% during the forecast period, with a market size of USD XX million in 2024.
• The Portugal Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 10.9% during the forecast period, with a market size of USD XX million in 2024.
• The Greece Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 11.4% during the forecast period, with a market size of USD XX million in 2024.
• Rest of Europe's Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD XX million in 2024.

Asia Pacific Circulating Biomarker for Liquid Biopsy Market

According to Cognitive Market Research, the global Circulating Biomarker for Liquid Biopsy market size was estimated at USD XX Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.6% from 2024 to 2031.

• According to Cognitive Market Research, the China Circulating Biomarker for Liquid Biopsy market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 14.1% during the forecast period. Circulating Biomarker for Liquid Biopsy surged in China due to the rising cancer prevalence.
• The Japan Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 13.1% during the forecast period, with a market size of USD XX million in 2024.
• The India Circulating Biomarker for Liquid Biopsy market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 16.4% during the forecast period. India's aging population.
• The South Korean Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 13.7% during the forecast period, with a market size of USD XX million in 2024.
• The Australian Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 14.3% during the forecast period, with a market size of USD XX million in 2024.
• The South East Asia Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 15.6% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of Asia Pacific Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 14.4% during the forecast period, with a market size of USD XX million in 2024.

South America Circulating Biomarker for Liquid Biopsy Market

According to Cognitive Market Research, the global Circulating Biomarker for Liquid Biopsy market size was estimated at USD XX Million, out of which the Latin America market has more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.0% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil Circulating Biomarker for Liquid Biopsy market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 12.6% during the forecast period. Circulating Biomarker for Liquid Biopsys flourished in Brazil due to the increased r&d.
• Argentina's Circulating Biomarker for Liquid Biopsy market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 12.9% during the forecast period. Argentina's government funding.
• Colombia Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 11.8% during the forecast period, with a market size of USD XX million in 2024.
• Peru Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 12.2% during the forecast period, with a market size of USD XX million in 2024.
• Chile Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 12.3% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of Latin America's Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 11.1% during the forecast period, with a market size of USD XX million in 2024.

Middle East and Africa Circulating Biomarker for Liquid Biopsy Market

According to Cognitive Market Research, the global Circulating Biomarker for Liquid Biopsy market size was estimated at USD XX Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.3% from 2024 to 2031..

• The GCC Countries Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 13.1% during the forecast period, with a market size of USD XX million in 2024. Circulating Biomarker for Liquid Biopsy sales flourish due to the regulatory approvals.
• The Egypt Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 12.6% during the forecast period, with a market size of USD XX million in 2024.
• The South Africa Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 13.3% during the forecast period, with a market size of USD XX million in 2024. Circulating Biomarker for Liquid Biopsy sales flourish in South Africa due to growing healthcare awareness.
• The Turkey Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 11.8% during the forecast period, with a market size of USD XX million in 2024.
• The Nigeria Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 11.4% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of MEA Circulating Biomarker for Liquid Biopsy market is projected to witness growth at a CAGR of 11.3% during the forecast period, with a market size of USD XX million in 2024.

Circulating Biomarker for Liquid Biopsy Market Analysis

How are Segments Performing in the Global Circulating Biomarker for Liquid Biopsy Market?

Circulating Biomarker for Liquid Biopsy Market Diagnosis Method Segment Analysis

According to Cognitive Market Research, Blood Tests stands out as the dominant category over the projected period. Blood checks are fueling the growth of the circulating biomarker for the liquid biopsy market by offering a non-invasive, green approach to cancer detection and tracking. Advances in blood-based diagnostic technology enhance the sensitivity and accuracy of detecting biomarkers like ctDNA and CTCs. This fashion supports the market's expansion, pushed by a call for early and customized cancer care.

Saliva Tests emerges as the fastest-growing category in the Circulating Biomarker for Liquid Biopsy market. Saliva tests are driving the increase in the circulating biomarker for the liquid biopsy market by presenting a non-invasive, convenient alternative to blood checks. Advances in saliva-based total diagnostics permit the detection of biomarkers associated with numerous cancers, imparting a person-pleasant and on-hand method for early detection and tracking. This innovation supports marketplace growth by way of enhancing diagnostic alternatives and patient consolation.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Circulating Biomarker for Liquid Biopsy Industry. Request a Free Sample PDF!

Circulating Biomarker for Liquid Biopsy Market Application Segment Analysis

According to Cognitive Market Research, the dominant category is Cancer Detection. Cancer detection is accelerating the increase of the circulating biomarker for liquid biopsy marketplace with the aid of highlighting the need for early, non-invasive diagnostic techniques. Liquid biopsies, which examine biomarkers in blood or other fluids, offer widespread benefits in detecting tumors at an early degree and monitoring treatment responses, driving improved adoption and funding in this modern diagnostic field.

The fastest-growing category in the Circulating Biomarker for Liquid Biopsy market is Infectious Disease. Infectious disease is expanding the circulating biomarker for liquid biopsy marketplace via emphasizing the want for non-invasive diagnostic strategies to become aware of and display pathogens. Liquid biopsies, which may examine biomarkers in fluids like blood, are being explored for their ability to detect infections early and track disorder development, riding innovation and increasing this diagnostic zone.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Circulating Biomarker for Liquid Biopsy End-User Segment Analysis

Circulating Biomarker for Liquid Biopsy Market End-User Segment Analysis

According to Cognitive Market Research, the dominant category is Hospitals. Hospitals are using the boom of the circulating biomarker for the liquid biopsy market by adopting advanced diagnostic technology for most cancers and different illnesses. Increased integration of liquid biopsy techniques into routine medical practices enhances patient care through non-invasive trying out and real-time tracking. This adoption helps marketplace expansion, as hospitals are seeking green and accurate diagnostic equipment to improve patient consequences.

The fastest-growing category in the Circulating Biomarker for Liquid Biopsy market is Diagnostic Labs. Diagnostic labs are fueling the boom of the circulating biomarker for the liquid biopsy market by incorporating superior technologies into their testing offerings. The call for correct, non-invasive diagnostic equipment drives labs to provide liquid biopsy solutions for early cancer detection and monitoring. This fashion enhances marketplace enlargement as labs undertake and innovate with cutting-edge diagnostic techniques.

• Hospitals
• Diagnostic Labs
• Applied Markets
• Bio Banking
• Academic Research Institute

Author's Detail

Kalyani Raje

Senior Research Analyst at Cognitive Market Research

LinkedIn

Profile

An optimistic Senior Research Analyst with years of experience in competitive assessment and business consulting. A seasoned professional and subject-matter expert (SME) in the Automobile & Transportation vertical.

Author's Conclusion